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Study Hypothesis
Population genetic studies have established the role of natriuretic peptide system in blood pressure (BP) regulation. 2 The primary function of atrial natriuretic peptide (ANP) is to induce natriuresis through kidneys and promote vasodilatation in blood vessels. Clinical trials have shown that glucagon-like peptide-1 receptor (GLP-1R) agonists reduce BP and decrease cardiovascular risk. 3 In the current study, Kim et al 1 uncover a novel link between GLP-1R and ANP, possibly elucidating the mechanism behind the reduction of BP that is observed with the use of GLP-1R agonists in clinical trials.
How Was the Hypothesis Tested?
The authors 1 used Glp1r −/− mice, Nppa −/− mice, and Rapgef4 −/− mice (all on the C57BL/6 background) with the corresponding wild-type controls. Angiotensin II infusion and pressure overload secondary to transaortic constriction were used to induce hypertension in the mice. The authors tested whether liraglutide (GLP-1R agonist) infusion in the normotensive and hypertensive mice reduced BP, induced ANP secretion, and promoted aortic vasodilatation. Next, they determined the importance of ANP for the antihypertensive actions of liraglutide using ANP knockout (Nppa −/− ) mice. Finally, the authors used Rapgef4 −/− mice, which are deficient of the gene encoding the downstream effector, Rap guanine nucleotide exchange factor Epac2 (also known as Rap-gef4), to determine the importance of Epac2 for the stimulatory effect of liraglutide on ANP secretion and its ability to lower BP.
Principal Findings
GLP-1R expression was localized to atrial cardiomyocytes in both normotensive and hypertensive mice. Liraglutide produced a significant reduction in both systolic and diastolic BP in wild-type mice after angiotensin II infusion but did not reduce BP in the Glp1r −/− mice. Mice pretreated with natriuretic peptide receptor antagonist blocked the antihypertensive effects of liraglutide. Further, liraglutide did not directly increase cyclic GMP or relax preconstricted aortic rings.
Liraglutide infusion increased urinary sodium excretion in normotensive and hypertensive wild-type mice, but there was neither a reduction in BP nor an increase in urinary sodium excretion in the Nppa −/− mice. These findings suggest an indirect ANP-dependent effect. Moreover, in both normotensive and hypertensive mice, the liraglutide-induced ANP secretion from cardiomyocytes was mediated by the activation of the downstream effector, Rap guanine nucleotide exchange factor Epac2 (also known as Rapgef4), because plasma ANP levels failed to increase in Rapgef4 −/− mice after treatment with liraglutide. Expression of adenoviral Epac2 in atrial cardiomyocytes from hypertensive Rapgef4 −/− mice restored the ability of liraglutide to induce ANP secretion from the cardiomyocytes. In addition, liraglutide significantly lowered both systolic and diastolic BP in hypertensive wild-type mice but had no effect on BP in hypertensive Rapgef4 −/− mice. Taken together, these results suggest that liraglutide induces the release of ANP via a GLP-1R/Epac2 signaling pathway mechanism and regulates BP in a GLP-1R-ANP-dependent manner.
Implications
This study uncovers a novel gut-heart axis by which a gut hormone, GLP-1, regulates ANP secretion from cardiomyocytes and lowers BP. One could speculate that these findings can be translated to treating hypertension in humans especially in patients with coexisting diabetes mellitus. Further research directed at pharmacologically augmenting the activation of natriuretic peptide system through GLP-1R pathway is warranted.
